Alexion rises on Roche buyout rumor; no comment from companies
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals could command a high price for its rare disease-focused portfolio, but the company and purported suitor Roche have not confirmed or denied that the Swiss pharma giant is interested in buying the US biotechnology company.